Breast Cancer

Mammography facilities are now nationally required to inform patients about their breast density, which can affect cancer detection.

Using artificial intelligence (AI) in breast cancer screenings in the United Kingdom could be cost-effective and improve health outcomes after identifying more cancers.

While it can seem overwhelming or difficult to decide where to start addressing racial and ethnic disparities in health care, the key is to focus on a manageable area that can be built upon.

A new review highlights the urgent need for research-driven solutions in breast cancer to enhance early detection, treatment, and patient support across diverse populations.

Demetria Smith-Graziani, MD, MPH, Emory University School of Medicine, explained biological and structural obstacles to equitable breast cancer outcomes and care across racial and ethnic groups.

Artificial intelligence (AI) can aid in breast cancer detection, but radiologists need training to ensure accuracy and prevent missed cancers.

A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.

Harold "Hal" Burstein, MD, PhD, emphasizes the crucial role of strong patient-physician partnerships in breast cancer treatment, empowering patients through shared decision-making.

The COVID-19 pandemic disrupted breast cancer screenings, leading to decreased follow-up rates and widening health disparities.

Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.

Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.

The risk of early-onset breast cancer, particularly luminal A and triple-negative subtypes, was higher in Black women with obesity and high leptin levels compared with White women. This research highlights the urgent need for targeted interventions to address racial disparities in breast cancer outcomes.

Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.

A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.

A medical expert navigates toxicity management in patients being treated with ribociclib.

Dr. Rugo details her management strategy in regards to GI toxicities.

Despite numerous trials, breast cancer immunotherapies have had a modest clinical impact, with only 2 approved drugs, highlighting inefficiencies in the clinical trial system.

Despite a significant increase in women with unilateral breast cancer who received a bilateral mastectomy, this study found no survival benefit compared with other treatment options. Although removing the unaffected breast reduces the risk of developing cancer in the other breast, results did not show decreased risk of death from breast cancer.

Study results suggest hormone therapy after breast cancer may lower dementia risk, particularly for younger Black women, but further research is needed to confirm these findings.

A remote monitoring app with alerts for doctors did not improve medication adherence in patients with breast cancer, but those receiving tailored text messages on top of monitoring saw reduced high-cost health care use.

Breast-conserving therapy for BRCA1/2 mutation carriers has higher risks of future breast cancers than the general population, but most patients avoid another cancer event, and many remain bilateral mastectomy–free after 20 years.

Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.

A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.

Early data suggest that BLU-222 combined with ribociclib and fulvestrant is safe and tolerable for patients with HR-positive and HER2-negative breast cancer, potentially overcoming resistance to CDK4/6 inhibitors.

The FDA approved SH-105 (Tepylute) prediluted injectable treatment for breast and ovarian cancers. This innovative formulation eliminates the need for complex powder reconstitution, improving safety and patient care.

Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score potentially identifying those at higher risk of recurrence.

A Swedish study suggests bariatric surgery may lower breast cancer risk in obese women, particularly those with high insulin levels at baseline.

This study highlights the lack of clear guidelines for breast cancer management in transgender men after chest contouring surgery. While data is limited, the authors suggest adapting existing recommendations for cisgender women and implementing risk management strategies like pre-surgery evaluation and education.

A recent study found that neighborhood deprivation is associated with higher breast cancer death rates for non-Hispanic White women, but not Black women. This suggests factors beyond socioeconomic status contribute to the racial disparity.

The use of a novel digital health platform achieved a 55% reduction in time to treatment among women with a new diagnosis of breast cancer.